Neurofunctional Reversibility in Psoriasis Vulgaris After IL-17A Inhibition: A Resting-State fMRI and Neurocognitive Analysis
Psoriasis is associated with brain dysfunction and neuropsychiatric symptoms. IL-17A antibody therapy improves skin symptoms, restores brain function, and alleviates neuropsychiatric issues vs untreated patients, supporting multidimensional treatment.
Authors
- Huiping Fan (ORCID: https://orcid.org/0000-0001-8424-2792)
- Jiayun Liu (ORCID: https://orcid.org/0009-0001-9048-3709)
- Yunyan Pang (ORCID: https://orcid.org/0009-0004-9212-3127)
- Dong Zhang (ORCID: https://orcid.org/0000-0002-0621-0645)
- Xu Chen (ORCID: https://orcid.org/0000-0001-9506-1815)
- Xiaojin Li (ORCID: https://orcid.org/0000-0002-6525-8585)
- Rui Sun (ORCID: https://orcid.org/0000-0003-3718-5849)
- W Ma (ORCID: https://orcid.org/0009-0001-0593-1299)
- Qingsong Ma
Institutions
- Weifang Medical University (CN)
- Second Hospital of Shandong University (CN)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/ptt.s554255
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00